Free Trial

Anebulo Pharmaceuticals (ANEB) Competitors

Anebulo Pharmaceuticals logo
$2.58 +0.08 (+3.20%)
Closing price 04:00 PM Eastern
Extended Trading
$2.58 +0.00 (+0.19%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANEB vs. YMAB, AQST, RGNX, VIGL, ATXS, CAPR, NBTX, AURA, ESPR, and FULC

Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Y-mAbs Therapeutics (YMAB), Aquestive Therapeutics (AQST), REGENXBIO (RGNX), Vigil Neuroscience (VIGL), Astria Therapeutics (ATXS), Capricor Therapeutics (CAPR), Nanobiotix (NBTX), Aura Biosciences (AURA), Esperion Therapeutics (ESPR), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry.

Anebulo Pharmaceuticals vs. Its Competitors

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anebulo Pharmaceuticals presently has a consensus price target of $5.50, indicating a potential upside of 113.18%. Y-mAbs Therapeutics has a consensus price target of $9.62, indicating a potential upside of 12.94%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Anebulo Pharmaceuticals is more favorable than Y-mAbs Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anebulo Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Y-mAbs Therapeutics
2 Sell rating(s)
8 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, Anebulo Pharmaceuticals had 3 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 5 mentions for Anebulo Pharmaceuticals and 2 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 0.91 beat Anebulo Pharmaceuticals' score of 0.76 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anebulo Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Y-mAbs Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Anebulo Pharmaceuticals has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-9.92
Y-mAbs Therapeutics$87.68M4.42-$29.67M-$0.50-17.04

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.60% beat Anebulo Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Anebulo PharmaceuticalsN/A -90.11% -84.53%
Y-mAbs Therapeutics -26.03%-24.60%-18.89%

Summary

Anebulo Pharmaceuticals beats Y-mAbs Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANEB vs. The Competition

MetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$105.99M$3.12B$5.70B$9.79B
Dividend YieldN/A2.21%3.77%4.10%
P/E Ratio-9.9220.7930.8625.27
Price / SalesN/A232.09403.8888.61
Price / CashN/A41.5625.2228.45
Price / Book17.209.749.516.00
Net Income-$8.20M-$54.74M$3.26B$265.34M
7 Day Performance8.86%8.13%4.50%2.79%
1 Month Performance57.32%7.74%5.22%1.51%
1 Year Performance30.30%18.08%31.92%25.40%

Anebulo Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANEB
Anebulo Pharmaceuticals
2.2333 of 5 stars
$2.58
+3.2%
$5.50
+113.2%
+26.3%$105.99MN/A-9.924
YMAB
Y-mAbs Therapeutics
2.6763 of 5 stars
$8.52
-0.1%
$11.16
+31.1%
-30.4%$385.56M$87.68M-17.03150Positive News
AQST
Aquestive Therapeutics
2.1083 of 5 stars
$3.90
+0.9%
$10.14
+160.4%
-3.1%$385.50M$57.56M-6.58160Earnings Report
Analyst Revision
RGNX
REGENXBIO
4.2652 of 5 stars
$7.60
+1.9%
$28.38
+273.4%
-28.0%$384.89M$83.33M-2.22370
VIGL
Vigil Neuroscience
3.2872 of 5 stars
$8.05
flat
$10.80
+34.2%
N/A$383.91MN/A-3.9340
ATXS
Astria Therapeutics
2.6927 of 5 stars
$6.58
-1.5%
$29.00
+340.7%
-38.7%$370.18MN/A-3.5130News Coverage
Earnings Report
Analyst Revision
CAPR
Capricor Therapeutics
3.0245 of 5 stars
$7.86
+0.5%
$22.56
+187.0%
+101.0%$356.12M$22.27M-5.49101Trending News
Earnings Report
Analyst Revision
Gap Down
NBTX
Nanobiotix
0.8208 of 5 stars
$7.37
+0.3%
$8.00
+8.5%
+59.8%$353.32M$39.18M0.00100News Coverage
Short Interest ↑
Gap Up
AURA
Aura Biosciences
1.6563 of 5 stars
$7.00
+2.3%
$22.00
+214.5%
-14.7%$349.88MN/A-3.6650News Coverage
Earnings Report
Analyst Revision
ESPR
Esperion Therapeutics
4.0321 of 5 stars
$1.77
-4.3%
$7.00
+296.6%
+4.6%$349.82M$332.31M-3.60200Analyst Upgrade
FULC
Fulcrum Therapeutics
1.3605 of 5 stars
$6.42
+1.2%
$7.57
+18.0%
-26.2%$346.72M$80M-5.25100

Related Companies and Tools


This page (NASDAQ:ANEB) was last updated on 8/18/2025 by MarketBeat.com Staff
From Our Partners